[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.157.140. Please contact the publisher to request reinstatement.
Correspondence
July 2004

Use of SCORTEN to Accurately Predict Mortality in Patients With Toxic Epidermal Necrolysis in the United States

Arch Dermatol. 2004;140(7):890-892. doi:10.1001/archderm.140.7.890

The SCORTEN is an illness severity score specific to toxic epidermal necrolysis (TEN) developed and validated in Europe by Bastuji-Garin et al.1 Recently, 2 reports of the use of the SCORTEN toassess the changes in mortality in patients treated with intravenous immune globulin have shown contradictory results, bringing into question the applicabilityof the SCORTEN outside Europe.2,3 We therefore retrospectively analyzed our patients with TEN before using intravenousimmune globulin to determine whether the SCORTEN would accurately predict mortality.

×